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Put to the test: use of rapid testing technologies for covid-19
Alex Crozier and colleagues look at how new technologies can be most appropriately used to
support different testing strategies and examine the benefits and risks
Alex Crozier, 1 Selina Rajan, 2 Iain Buchan, 3 Martin McKee2, 4
Governments have invested enormous resources in
scaling up testing capacity in their responses to
covid-19. Real-time reverse transcription polymerase
chain reaction (PCR) was the first, and still the most
widely used, test. However, several days can elapse
between requesting a test and getting and acting on
a result, leaving a window in which infection may
spread.A further problem is that peoplemay transmit
infectionbefore recognising symptoms1—akeydriver
of spread. In addition, some people who remain
asymptomatic have a similar viral load to those who
develop symptomsandmayalso contribute to spread,
although the extent of this is unclear.1 -3 Given the
importance of presymptomatic or paucisymptomatic
transmission,1 measures that shorten the time
between testing and results are essential for
minimising onward transmission. It is difficult to
achieve this with large scale PCR testing.
Rapid antigen lateral flow tests offer an alternative.
They provide a rapid result but are less able to detect
infections.4 Governments are purchasing them in
large quantities, with some seeing a single test as a
way to free an individual fromquarantineobligations,
a view not supported by the World Health
Organization.4 However, repeated lateral flow testing
may have value in combination with other measures.
In Liverpool, UK, for example, authorities are
examining test-to-protect, test-to-release (from
quarantine), and test-to-enable (safer return to
restricted activities) regimens, alongside outbreak
response and public open access to lateral flow
testing.5 Such real world evaluations are needed to
understand how these models work in different
populations and settings, how they influence
behaviour, and the contribution of lateral flow tests
to overall strategies, where they have the potential
to interrupt transmission while reducing the
mounting harms from restrictions.
Interpreting test results
Meaningful interpretation of any test requires
knowledge of its sensitivity (proportion of infected
people who test positive), specificity (proportion of
non-infected people who test negative), and pre-test
probability that an individual is infected, reflecting
population prevalence and the individual’s
circumstances.6
Although controls within assays minimise errors,
technical problems during sample collection,
processing, or reporting can give false results. Lateral
flow tests produce very few false positive results, and
in a low prevalence setting these can be detected by
confirmatory PCR testing.4 7 False negative results
are more concerning. Besides technical errors, they
can arise in people tested during the 5-7 day
incubation period before the viral antigen shed in the
nose and throat is sufficient to be detected, usually
1-2 days before symptom onset.1 2 8 Taking swabs
requires skill, and swabs taken by untrained
individuals are more likely to give false negative
results.9 10 False negatives might create a false sense
of security, paradoxically increasing transmission
risk.11
Conversely, PCR testing is overly sensitive, detecting
viral shedding long after the infectious period (about
9 days), with people continuing to test positive for a
mean of 17 days.2 Although such positive results are
technically correct, these people are not infectious
and should not be quarantined. Moreover, any test
is just a snapshot of the moment the sample was
taken.
A shared understanding of the utility and
uncertainties of these tests is key to using them well
(see bmj.com for a full analysis).12 Effective
communication of what results mean is paramount.
Novel tests
Several novel techniques, such as loop mediated
isothermal amplification,next generation sequencing
(LamPORE), point-of-care PCR, and lateral flow tests
are in different stages of development, validation,
approval, and implementation (see appendix table 1
on bmj.com). Each has advantages and limitations,
so the choice depends on the intended use. Lateral
flow tests (table 1) aim to detect only infectious cases,
can be scaled up quickly for decentralised testing,
are relatively cheap, do not require laboratories, and
provide results rapidly. As such, they are most
appropriate for widespread community testing
intended to reduce transmission or time spent in
isolation, and to enable economic and social activities
to restart. Lateral flow tests are less sensitive than
nucleic acid amplification tests such as PCR,
generating more false negative results if used as a
test of infection rather than infectiousness, and they
are particularly susceptible to sampling quality.4 13
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Table 1 | Advantages and limitations of lateral flow tests compared with PCR tests*
LimitationsAdvantages
Some infectious individuals will have negative resultsRapid time to results (10-30 minutes)
End-to-end single test performance falls when used by untrained staff or public—less so when
repeated
Does not need laboratory analysis and so can facilitate frequent decentralised testing at scale
Infectious window is early and short lived, narrowing the window to find cases before they
transmit infection
Good detector of the most infectious cases and less likely to detect post-infectious people with
residual shedding
Current lateral flow test does not quantify the level of virus material detected to reflect a level
of infectiousness
Effective contact tracing depends on speed, and modelling suggests testing frequency and
speed of reporting more important than sensitivity alone for surveillance and controlling
transmission
* See appendix for performance results.
The window for using lateral flow tests to detect infectious cases is
narrow.2 14 They are most suitable when testing is frequent, as we
explain below, and the goal is detection of cases with high viral
shedding immediately before and after symptom onset.2 4 Despite
their limitations, their ability to provide near instantaneous results
avoids thedelays associatedwithPCRand facilitates timely isolation
of the most infectious cases and their close contacts,4 15 who may
otherwise transmit infection while waiting for a PCR result.
Although lateral flow tests have a higher risk of false negative
results, in theory the rapid increase in viral shedding after the
incubation period leaves only a short period when there will be a
substantial differencebetween thepointwhenyouget a first positive
result on a highly sensitive test (PCR) compared with a lower
sensitivity test (lateral flow).16 17 Importantly, modelling suggests
more frequent testing with lower sensitivity tests can achieve the
same probability of detecting a case as less frequent testing with
higher sensitivity tests (fig 1).18 19 Under laboratory conditions, the
limit of the detection capacity of lateral flow tests largely aligns
with the quantities of viral shedding (quantified as viral load) and
ability to culture virus typically observed at the end of the first week
of symptoms,14 20 after which most patients cease being infectious.2
Fig 1 | High frequency testing with low analytic sensitivity versus low frequency testing with high analytic sensitivity. A person’s infection trajectory (blue line) is shown in
the context of two surveillance regimens (circles) with different analytic sensitivity. Higher frequency testing is more likely to test in the infectious window. Therefore,
although both testing regimens detect the infection (orange circles), the high frequency lateral flow test is more likely to detect it during the transmission window (shading),
despite its lower analytic sensitivity. The figure is not an accurate representation of exactly when a positive test is likely to signify that a case is infectious. Adapted with
permission from Mina et al16 with data from Cevik et al1 2
As detected viral antigen and cell culture infectivity are proxies and
not direct indicators of infectiousness, caveats remain, but the point
when lateral flow test results change from negative to positive, and
vice versa, mostly coincides with the beginning and end of
infectiousness of most symptomatic cases,14 and potentially also
in asymptomatic cases. Furthermore, analysis of national PCR and
the bmj | BMJ 2021;372:n208 | doi: 10.1136/bmj.n2082
ANALYSIS
contact tracing data showed that cases with high viral load are the
most infectious (that is, infect more of their contacts) and that,
under laboratory conditions, the best performing lateral flow tests
detect 91% of cases that lead to onward transmission (based on
modelled estimateswith implicit uncertainty anddynamics).21 Thus,
despite their lower sensitivity, lateral flow tests may be a useful
indicator of current infectivity and less likely than PCR to detect
post-infectious shedders.
Test sensitivity is operator dependent,10 and self-swabbing in real
world conditions is likely to miss more infections than swabbing in
controlled conditions. In the Liverpool community testing pilot,
samples were obtained by self-swabbing under supervision of
soldiers, and lateral flow tests missed 60% of PCR positive cases.2 5
However, over half of these people with positive PCR results were
likely to be post-infectious shedders, consistent with the low and
fallingprevalence inLiverpool at the time (see appendix).5 Although
furtherwork is required to determinehowdetected viral load relates
to infectiousness, data suggest lateral flow tests missed less than a
third of people likely to be infectious.5 21 Use and interpretation of
lateral flow devices can improve with more robust operating
procedures, additional training, and possibly AI augmented
reading.5 10 Antigen tests and population groups are also
heterogenous, so test accuracy must be understood for different
groups (eg, asymptomatic or paucisymptomatic, and by age and
background prevalence) before large scale use.
Testing strategies
Countries have adopted different testing strategies, many using
lateral flow tests (fig 2). Their benefits and risks are summarised in
the appendix on bmj.com. Each should be evaluated, recognising
that testing can only be one part of a comprehensive pandemic
response.Whendecidingwhich test to adopt, andhow to implement
it, system-wide practicalities must be considered, especially
accessibility and acceptability of sampling, turnaround times, and
re-test intervals.
Fig 2 | Principal testing strategies and examples of countries deploying them. Summary of the benefits and risks of each testing strategy and the biochemical limitations and
other challenges to large scale asymptomatic testing are described in the appendix on bmj.com
Mass testing
The effectiveness, feasibility, opportunity costs, and ethics of large
scale asymptomatic testing are fiercely debated. Some have likened
this to cancer screening programmes, but the pandemic context is
quite different. Cancer screening aims to benefit the individual
whereas testing for thepresence of highly transmissible respiratory
infections is to protect others by breaking transmission chains.
Mass (repeat) testing for SARS-CoV-2 using PCR in China, Vietnam,
and Iceland and lateral flow tests in Slovakia has identified cases
that would have gone undetected. However, mass testing poses
tremendous logistical challenges, requiring considerable resources
and careful planning. In the UK, non-focused mass repeat testing
is unlikely to be feasible or cost effective.
SMART
Liverpool, UK, has developed a focused approach to community
testing with lateral flow tests called SMART (systematic meaningful
asymptomatic repeated testing). Open access testing of the public
is supported by communications and outreach targeting specific
groups that are vulnerable to covid-19 or its control measures.
SMART comprises a dual strategy of focused reduction in
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transmission alongside outbreak response and specific
test-to-protect, test-to-enable, and test-to-release schemesdesigned
to protect key services, reconnect societies, and recover the
economy. The benefits and risks of the scheme are monitored
through public health, healthcare, and administrative data and
continuous qualitative information gathering. This information is
used to adapt the evolvingprogramme inweekly reviews, co-created
with community groups. For example, when the UK introduced a
national lockdown at the start of 2021, testing in Liverpool focused
on workplaces to enable continuity of essential services and to
protect against transmission in high mixing environments such as
supermarkets. Positive lateral flow results are confirmed with PCR
and viral genetic sequencing.
Although SMART has considerable potential to find asymptomatic
or paucisymptomatic cases early and reduce onwards transmission,
large scale use is resource intensive and requires effective local
engagement. Participation in mass testing in China, Vietnam, and
Slovakia was compulsory, with quarantine enforced and
consequences for non-adherence. Given the importance of
presymptomatic andpaucisymptomatic transmission, SMARTmust
findmore cases in the incubationperiod to improve on symptomatic
testing, which in theory it should, while reducing the risks from
false negative results. Up to 21 January 2021, 359 606 lateral flow
tests had been done on 205 836 Liverpool residents, identifying 4421
people who may not have otherwise known they were likely to be
infectious (CIPHA dashboard data, available from authors on
request). Thesepeoplewere thenable to self-isolate, breaking chains
of onward transmission.
Although the behavioural responses to large scale asymptomatic
testing in the community are not fully understood, particularly the
potential increase in hazardous behaviours following a negative
result, Office for National Statistics survey data in Liverpool showed
most (62%) said a negative result would be unlikely to cause them
to change their behaviour.5 However, some said they were more
likely to visit friends (9%) or go towork (7%), emphasising theneed
to communicate the importance of maintaining covid safe
behaviours. The considerable advantages of identifying infectious
cases early to break transmission chains must be balanced against
any potential false reassurance given to people with false negative
results and the risks that confirmed cases do not isolate. This
balance, andprogrammecost effectiveness, are the keys to realising
the net benefits of SMART.
Although 95% of positive cases in the Liverpool pilot self-isolated
and informed relevant contacts immediately, not beingable to afford
the costs of self-isolation was a substantial barrier to uptake,5
highlighting the need for a holistic public health approach,
including effective communication and comprehensive support to
self-isolate. Tests alone are not the answer: recent experience of
repeat lateral flow testing in German care homes highlights the
many logistical, economical, and behavioural challenges of
SMART.22
Logistical factors are important, such as arrangements for booking
and queuing for tests, so the choice of test policy will often be
limited by cost, availableworkforce, and capacity of the community
to access booking systems and testing sites. The biological,
behavioural, ethical, and system implications of complex public
health interventions such as SMART must be evaluated, with
findings used to develop rigorous standard operating procedures
and protocols that optimise strategies (fig 3). Communicating this
evidence clearly is essential to achieve the? public and professional
trust needed if testing is to succeed.
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Fig 3 | Keys to successful SMART (systematic meaningful asymptomatic repeated testing) programme
Improving cluster identification and outbreak response
It takes 4-5 days for someone infected with SARS-CoV-2 to infect
another person so contact tracing must identify and reach contacts
as soon as possible.23 As many people don’t request a test until at
least 24-48hours after developing symptomsandPCRcan takemore
than 48 hours to return results (median 38 hours with 14% taking
over 72 hours most recently in England24), substantial onwards
transmission can occur before contacts are reached and clusters of
cases can quickly develop into large outbreaks. Modelling suggests
rapid and frequent testing can help to reduce transmission.19 25 In
high risk settings for outbreaks (workplaces, care homes, schools,
universities, prisons, and hospitals), repeated and frequent lateral
flow tests cut these delays, providing real time results for cases and
close exposure contacts, which can identify clusters26 quickly and
limit spread. Tomitigate the increased risks of false negative results,
people with symptoms could have lateral flow and PCR tests in
parallel. Robust communication that a negative lateral flow result
doesnotmean “not infectious” is essential, and symptomatic people
must continue to isolate.
Cases could also be identified earlier if the clinical case definition
were broadened to include symptoms such as disturbance (rather
than loss) of taste and smell, headaches, and myalgia, which often
present earlier than the classic symptoms. Although existing testing
capacity might struggle, a broader definition would be more
consistent with WHO criteria27 and should be evaluated. Outbreak
response and community testing canalso be improvedusingmobile
or pop-up PCR or LamPORE laboratories, which can provide
relatively high throughput sensitive testing with a turnaround time
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of 4-24 hours. Cluster identification can also be improved by using
genomic sequencing technology, which can inform contact tracing
and potentially reduce transmission.28
Test to protect
If implemented carefully, repeated testing in high infection risk
settings can protect people who are either clinically vulnerable or
vulnerable to infection (and transmission).29 Although the high
sensitivity of the PCR test favours its use in vulnerable settings, it
can takedays from requesting a swab to getting the result. Frequent,
rapid decentralised lateral flow testing may prove more effective.
The recent policy of bi-weekly testing of NHS staff with lateral flow
tests recognises that frequent testing can compensate for reduced
sensitivity. Specific testing strategies may also be focused on
protecting groups most susceptible to infection and transmission,
such as key workers, enabling continuity of essential services and
possibly reducingoverall transmission.Again, communicationmust
be clear that a negative result does not necessarily mean a person
is non-infectious. Real world implementation and practicalities
must also be considered and optimised. Crucially, test-to-protect
policies will have limited effect unless workers are supported to
self-isolate.30 Weekly point-of-care PCR testing is also being
evaluated in some UK care homes, for both staff and visitors, but
more frequent lateral flow testing is also being evaluated and may
be more (cost) effective.
Test to release
Test-to-release models use repeated tests to reduce unnecessary
quarantine of non-infectious people, focusing isolation decisions
onpresumed infectivity rather than on infection. Variousmodelling
suggests that testing exposed contacts and international arrivals
can shorten the duration of isolation, which is likely to increase
compliance.31 32 PCR testing has been used as a way to shorten
unnecessary quarantine of non-infectious contacts, while daily
lateral flow testing is being piloted as a way to end unnecessary
quarantine of non-infectious contacts. However, PCR has a median
false negative rate of 38% five days after exposure and 20% on day
8 (although some assays showed near 100% detection at day 7).33
Althoughone study showedPCR testingonday7 reducedquarantine
time and resulted in no post-quarantine transmission,34 an
evaluation of test-to-release of household contacts showed that 19%
experienced symptoms or received a positive PCR test result after
testing negative seven days after the index case developed
symptoms,35 suggesting this is strategy is not without risk. Any
test-to-release policy must account for the incubation period,32
mitigate the risks of premature return or hazardous behaviours (see
bmj.com), and be shown to be cost effective. Ultimately, no test can
replace comprehensive support, both practical and financial,30 36
as a means of tackling low rates of self-isolation, particularly in
disadvantaged communities.
Test to enable
Test-to-enable policies seek to lift the current restrictions on social
contact that are causing wider public health and economic harms
in a way that minimises risk. For example, specific test-to-enable
strategies may be able to reduce the harms of social isolation by
enabling care home visiting, or to support workplaces in fragile
local economies to operate (with risk mitigation). Focused regular
testing is more logical than single tests for entry, which are unlikely
to confer population wide benefits.11 Context is key: disadvantaged
areas with greater mounting harms from measures to control
covid-19 could get most benefit from locally sensitive responses.
Again, however, practicalities and false negative results are
concerns, and we must await quality pilot data before any large
scale rollout.
Conclusion
Rapid tests provide new opportunities to find and isolate cases and
contacts early in the infection. However, implementing such tests
in local health systems is complex. Continued formative evaluation
is needed if such testing is to simultaneously reduce transmission
and alleviate the mounting harms from control measures. Pilots of
the SMART approach provide evidence of large scale, targeted use
of lateral flow tests. Successful approaches to control covid-19 must
facilitate earlier and better targeted isolation of the most infectious
people and their close contacts while, where the evidence supports,
releasing non-infectious contacts sooner from unnecessary
quarantine and returning to amore open society and economy. This
requires testing to be integrated into a comprehensive programme,
co-created with local leaders and communities, including effective
contact tracing, appropriate support and credible incentives for
those isolating, and strategic testing as part of ongoing surveillance
of vaccine effectiveness. A holistic public health approach, joined
up across towns, cities, and regions, is key to sustainable recovery
from the covid-19 pandemic.
Key messages
• Strategies for use of covid-19 tests vary widely between countries
• Rapid tests provide opportunities for early detection and isolation
but must be integrated into wider strategies to control transmission
• Assessment of the benefits and risks of different testing strategies
suggests how novel tests can be used in public health policies to
improve covid-19 resilience and recovery
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